Elise Biopharma is a specialized biopharmaceutical CDMO with dual hubs in Cambridge, Massachusetts, and Montréal, Canada—two of the world’s premier biotech innovation centers. We deliver end-to-end microbial biomanufacturing services focused on E. coli expression systems, precision fermentation, and custom bioprocess development. Backed by expert scientists and bioengineers, Elise combines deep technical expertise with operational agility to provide scalable, high-quality solutions for biologics, enzymes, proteins, and next-generation therapeutics.

Bioreactor

As a trusted E. coli CDMO partner, we support clients across the full development lifecycle—from early R&D and strain engineering to cGMP microbial fermentation, downstream purification, and analytical testing. Our facilities adhere to the highest standards of regulatory compliance and quality assurance, making us a reliable manufacturing partner for biotechs developing clinical or commercial-stage products.

At Elise, our mission is to empower innovation through collaborative, science-first partnerships. Whether you’re developing recombinant proteins, alternative proteins, or engineered biologics, we tailor our microbial fermentation services to fit your exact specifications and speed your time-to-market. With a passion for precision and a commitment to progress, Elise Biopharma is proud to enable the next wave of biomanufacturing breakthroughs—improving health outcomes and driving impact across healthcare, diagnostics, and industrial biotechnology.

Check out our services:

  • Microbial CDMO Services — High-titer E. coli and Pichia platforms that take enzymes, VLPs, and other recombinant proteins from 5 L feasibility to 2 000 L GMP with endotoxin routinely < 0.1 EU mg⁻¹.
  • mRNA CDMO Services — Plasmid prep, linear-template IVT, capping, LNP formulation, sterile fill-finish, and release assays—all validated for vaccine or gene-editing payloads.
  • Recombinant Proteins & Enzymes — Synthetic-biology strain design, AI-guided fed-batch control, and multimodal purification for therapeutic proteins and ISO 13485-grade diagnostic enzymes.
  • Fc-Fusion & Bispecifics — End-to-end design and GMP manufacture of albumin-fusions, Fc-extended cytokines, dual-target IgGs, and T-cell–engaging BiTEs.
  • Antibody Fragments & Nanobodies — scFv, Fab, diabody, and single-domain VHH production in secretion-tuned microbial hosts with rapid refold and polishing workflows.
  • Cytokines & Growth Factors — Engineered cytokines and regenerative growth factors expressed at >10 g L⁻¹, refolded and purified for high potency and ultra-low endotoxin.
  • Cell & Gene Therapy Services — GMP AAV/LVV vector suites, closed-system CAR-T/NK cell processing, and LN₂ logistics with full chain-of-identity documentation.
  • Cell Line Development — Codon-optimised vectors, CRISPR site-specific integration, single-cell cloning, and cGMP master/working cell banks.
  • Upstream Process Development — DoE-driven media/feed optimisation and digital-twin scale-up across 2 L–2 000 L batch, fed-batch, or perfusion.
  • Downstream Purification — Platform and custom trains (Protein A/G/L, IEX, HIC, SEC, continuous PCC) with integrated viral clearance or endotoxin polishing.
  • Formulation & Fill-Finish — Buffer/lyo design, high-concentration liquids, Grade A robotic isolators for vials, syringes, or cartridges, plus ICH stability.
  • Process Characterization — CPP/CQA mapping, scale-down models, three-batch PPQ, and Stage 3 CPV dashboards for regulatory assurance.
  • Contract Manufacturing — Clinical and commercial GMP slots with QP release, global logistics, and lifecycle cost-of-goods optimisation.
  • Custom Bioprocessing — Bespoke unit-op combinations, unusual feedstocks, or hybrid microbial/mammalian flows engineered to fit non-standard molecules.
  • Precision Fermentation — CRISPR-edited microbes plus AI process control to produce animal-free proteins, specialty enzymes, and sustainable food ingredients at commercial scale.
  • Glycoengineering — Host-cell glycosyltransferase editing and LC-MS fingerprinting to deliver bespoke fucosylation, sialylation, or bisecting GlcNAc profiles for biobetters.
  • Analytical & QC — In-house HR-MS, SEC-MALS, SPR/BLI, cell-based potency, and ICH stability labs that shorten method-transfer times and generate dossier-ready data.
  • Specialty & Emerging Modalities — Sandbox for bispecific T-cell engagers, nanobodies, scaffold proteins, and cell-free–expressed enzymes—rapid prototyping to GMP scale without extra tech-transfer steps.

Message us below and our team will be in touch soon. Thank you!

Email us directly at info@elisebiopharma.com